| scholarly article | Q13442814 |
| P50 | author | Yaxia Yuan | Q42880131 |
| Pamela Quizon | Q58204496 | ||
| Adrian M Gomez | Q64507805 | ||
| P2093 | author name string | Jun Zhu | |
| Narasimha M Midde | |||
| Chang-Guo Zhan | |||
| Wei-Lun Sun | |||
| P2860 | cites work | Eradication of HIV from the brain: reasons for pause | Q24612874 |
| X-ray structure of dopamine transporter elucidates antidepressant mechanism | Q24612997 | ||
| A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding | Q25938984 | ||
| Antidepressant binding site in a bacterial homologue of neurotransmitter transporters | Q27647095 | ||
| Structures of LeuT in bicelles define conformation and substrate binding in a membrane-like context | Q27676749 | ||
| HIV-1: fifteen proteins and an RNA | Q28284280 | ||
| Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse | Q28306056 | ||
| Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease | Q28365464 | ||
| Neural systems of reinforcement for drug addiction: from actions to habits to compulsion | Q29547251 | ||
| Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters | Q29616590 | ||
| The debate over dopamine's role in reward: the case for incentive salience | Q29618738 | ||
| Human immunodeficiency virus-1 Tat activates calpain proteases via the ryanodine receptor to enhance surface dopamine transporter levels and increase transporter-specific uptake and Vmax. | Q30497248 | ||
| HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors | Q32061182 | ||
| Molecular pathway involved in HIV-1-induced CNS pathology: role of viral regulatory protein, Tat. | Q33594713 | ||
| Hyperdopaminergic tone in HIV-1 protein treated rats and cocaine sensitization | Q33701016 | ||
| Correlation between errors on the Wisconsin Card Sorting Test and the availability of striatal dopamine transporters in healthy volunteers | Q33712203 | ||
| Neuronal death induced by brain-derived human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patients | Q33785357 | ||
| An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction | Q33930664 | ||
| HIV dementia: the role of the basal ganglia and dopaminergic systems | Q34098768 | ||
| Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia | Q34196506 | ||
| Environmental enrichment enhances sensitization to GBR 12935-induced activity and decreases dopamine transporter function in the medial prefrontal cortex | Q34284808 | ||
| Mutation of tyrosine 470 of human dopamine transporter is critical for HIV-1 Tat-induced inhibition of dopamine transport and transporter conformational transitions. | Q34343025 | ||
| HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study | Q34370880 | ||
| Mutations at tyrosine 88, lysine 92 and tyrosine 470 of human dopamine transporter result in an attenuation of HIV-1 Tat-induced inhibition of dopamine transport. | Q34458860 | ||
| Involvement of dopamine in the progression of AIDS Dementia Complex | Q34603500 | ||
| Genetically expressed HIV-1 viral proteins attenuate nicotine-induced behavioral sensitization and alter mesocorticolimbic ERK and CREB signaling in rats. | Q34969212 | ||
| CB2 receptor agonists protect human dopaminergic neurons against damage from HIV-1 gp120. | Q35023230 | ||
| Neuroimmunity and the blood-brain barrier: molecular regulation of leukocyte transmigration and viral entry into the nervous system with a focus on neuroAIDS. | Q35177355 | ||
| Molecular mechanism of HIV-1 Tat interacting with human dopamine transporter | Q35450098 | ||
| Cocaine and HIV-1 interplay: molecular mechanisms of action and addiction | Q35528967 | ||
| Neuropathologies in Transgenic Mice Expressing Human Immunodeficiency Virus Type 1 Tat Protein under the Regulation of the Astrocyte-Specific Glial Fibrillary Acidic Protein Promoter and Doxycycline | Q35749130 | ||
| Intra-ventral tegmental area HIV-1 Tat1-86 attenuates nicotine-mediated locomotor sensitization and alters mesocorticolimbic ERK and CREB signaling in rats | Q35757268 | ||
| Nicotine increases dopamine transporter function in rat striatum through a trafficking-independent mechanism | Q35893691 | ||
| Identification of a chloride ion binding site in Na+/Cl -dependent transporters. | Q35921659 | ||
| How dopamine transporter interacts with dopamine: insights from molecular modeling and simulation | Q36129055 | ||
| Increased Sensitivity to Cocaine Self-Administration in HIV-1 Transgenic Rats is Associated with Changes in Striatal Dopamine Transporter Binding. | Q36429675 | ||
| Expression of HIV-Tat protein is associated with learning and memory deficits in the mouse | Q36632791 | ||
| Recombinant human immunodeficiency virus-1 transactivator of transcription1-86 allosterically modulates dopamine transporter activity. | Q36912735 | ||
| Studies of the biogenic amine transporters. 12. Identification of novel partial inhibitors of amphetamine-induced dopamine release. | Q36926340 | ||
| Current understanding of HIV-associated neurocognitive disorders pathogenesis | Q36932005 | ||
| HIV-1 Tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomes | Q36944251 | ||
| In vivo microdialysis in awake, freely moving rats demonstrates HIV-1 Tat-induced alterations in dopamine transmission | Q36991639 | ||
| Nicotinic receptor activation increases [3H]dopamine uptake and cell surface expression of dopamine transporters in rat prefrontal cortex | Q37192709 | ||
| HIV-1 Tat protein-induced rapid and reversible decrease in [3H]dopamine uptake: dissociation of [3H]dopamine uptake and [3H]2beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (WIN 35,428) binding in rat striatal synaptosomes | Q37196323 | ||
| Evidence for developmental dopaminergic alterations in the human immunodeficiency virus-1 transgenic rat. | Q37238426 | ||
| Intra-accumbal Tat1-72 alters acute and sensitized responses to cocaine | Q37244423 | ||
| Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse | Q37314434 | ||
| Human immunodeficiency virus (HIV) infection of human macrophages is increased by dopamine: a bridge between HIV-associated neurologic disorders and drug abuse | Q37316522 | ||
| Role of Tat protein in HIV neuropathogenesis | Q37519397 | ||
| Neuropsychological consequences of HIV and substance abuse: a literature review and implications for treatment and future research. | Q37561360 | ||
| Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. | Q37702373 | ||
| Neurocognitive dysfunction in the highly active antiretroviral therapy era. | Q37966773 | ||
| The role of decision-making ability in HIV/AIDS: impact on prospective memory | Q39149169 | ||
| A psychomotor stimulant theory of addiction. | Q39681407 | ||
| Mechanism for cocaine blocking the transport of dopamine: insights from molecular modeling and dynamics simulations | Q39938422 | ||
| Entangled epidemics: cocaine use and HIV disease | Q40789555 | ||
| Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures | Q40886668 | ||
| Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. | Q41335848 | ||
| HIV-1 Nef expression in microglia disrupts dopaminergic and immune functions with associated mania-like behaviors | Q42232945 | ||
| Neurotoxicity of HIV-1 Tat protein: involvement of D1 dopamine receptor | Q42408293 | ||
| Cocaine enhances monocyte migration across the blood-brain barrier. Cocaine's connection to AIDS dementia and vasculitis? | Q42541038 | ||
| Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS. | Q42555161 | ||
| Increased dopaminergic neurotransmission in therapy-naïve asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses | Q43068310 | ||
| Dopamine D1 and D2 receptors influence dopamine transporter synthesis and degradation in the rat. | Q43641872 | ||
| Striatal dopamine transporters and cognitive functioning in healthy men and women | Q43726221 | ||
| Human dopamine transporter gene variation: effects of protein coding variants V55A and V382A on expression and uptake activities | Q44483562 | ||
| Methamphetamine-induced behavioral sensitization is enhanced in the HIV-1 transgenic rat. | Q44488415 | ||
| Decreased brain dopaminergic transporters in HIV-associated dementia patients | Q45023437 | ||
| Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains | Q45383832 | ||
| Detection of the human immunodeficiency virus regulatory protein tat in CNS tissues | Q45742328 | ||
| Environmental enrichment decreases cell surface expression of the dopamine transporter in rat medial prefrontal cortex | Q46526741 | ||
| Dysregulation of dopamine transporter trafficking and function after abstinence from cocaine self-administration in rats: evidence for differential regulation in caudate putamen and nucleus accumbens | Q46806034 | ||
| Abnormal striatal dopaminergic synapses in National NeuroAIDS Tissue Consortium subjects with HIV encephalitis | Q46880735 | ||
| A novel HIV-1 transgenic rat model of childhood HIV-1-associated nephropathy | Q47905079 | ||
| Individual differences in response to novelty predict prefrontal cortex dopamine transporter function and cell surface expression | Q48096780 | ||
| [3H]WIN 35,428 binding to the dopamine uptake carrier. II. Effect of membrane fractionation procedure and freezing | Q48201176 | ||
| Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis | Q48235017 | ||
| Dopamine transporter proline mutations influence dopamine uptake, cocaine analog recognition, and expression. | Q51408766 | ||
| The HIV-1 transgenic rat as a model for HIV-1 infected individuals on HAART. | Q54454547 | ||
| Cognitive dysfunction in HIV patients despite long-standing suppression of viremia | Q58074796 | ||
| Movement disorders and AIDS | Q69702990 | ||
| A prospective study of HIV disease progression in female and male drug users | Q77323334 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dopamine | Q170304 |
| striatum | Q1319792 | ||
| P304 | page(s) | 282-292 | |
| P577 | publication date | 2015-10-26 | |
| P1433 | published in | Journal of NeuroVirology | Q6295640 |
| P1476 | title | HIV-1 transgenic rats display an increase in [(3)H]dopamine uptake in the prefrontal cortex and striatum | |
| P478 | volume | 22 |
| Q30277012 | Expression profile of nicotinic acetylcholine receptor subunits in the brain of HIV-1 transgenic rats given chronic nicotine treatment |
| Q38812005 | HIV, Tat and dopamine transmission. |
| Q55309956 | HIV-1 proteins dysregulate motivational processes and dopamine circuitry. |
| Q90294828 | Role of Macrophage Dopamine Receptors in Mediating Cytokine Production: Implications for Neuroinflammation in the Context of HIV-Associated Neurocognitive Disorders |
| Q59812938 | Synaptic Connectivity in Medium Spiny Neurons of the Nucleus Accumbens: A Sex-Dependent Mechanism Underlying Apathy in the HIV-1 Transgenic Rat |
| Q38714925 | Tat-Mediated Induction of miRs-34a & -138 Promotes Astrocytic Activation via Downregulation of SIRT1: Implications for Aging in HAND. |
| Q41922188 | The role of human dopamine transporter in NeuroAIDS. |
Search more.